Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 14Carcinoma, Non-Small-Cell Lung 7Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma 1Peritoneal Neoplasms 1Ovarian Diseases 1Microsatellite Instability 1Gestational Trophoblastic Neoplasias (GTN) 1

Interventions

Carboplatin 159Paclitaxel 153Bevacizumab 85Taxes 48Gemcitabine 48liposomal doxorubicin 47Topotecan 41Cisplatin 35pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 21Drug Therapy 20Docetaxel 20niraparib 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 14rucaparib 13Nivolumab 12Cytoreduction Surgical Procedures 11Chemotherapy, Adjuvant 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × avelumab × Gynecologic × Clear all
NCT02915523 2024-01-10

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Syndax Pharmaceuticals

Phase 1/2 Completed
140 enrolled 25 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Diseases, Ovarian Neoplasms

NCT03704467 2020-11-13

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

EMD Serono

Phase 1 Completed
3 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03312114 2020-11-12

Anti-PD-L1 and SAbR for Ovarian Cancer

University of Texas Southwestern Medical Center

Phase 2 Terminated
5 enrolled 4 charts
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡